<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-01T01:09:40Z</responseDate><request verb="GetRecord" identifier="oai:docta.ucm.es:20.500.14352/95862" metadataPrefix="oai_dc">https://docta.ucm.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:docta.ucm.es:20.500.14352/95862</identifier><datestamp>2025-07-11T23:47:11Z</datestamp><setSpec>com_20.500.14352_14</setSpec><setSpec>col_20.500.14352_15</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation</dc:title>
   <dc:creator>Mac-Dowell Mata, Karina Soledad</dc:creator>
   <dc:creator>García Bueno, Borja</dc:creator>
   <dc:creator>Muñoz Madrigal, José Luis</dc:creator>
   <dc:creator>Parellada, Mara</dc:creator>
   <dc:creator>Arango López, Celso</dc:creator>
   <dc:creator>Micó, Juan A.</dc:creator>
   <dc:creator>Leza Cerro, Juan Carlos</dc:creator>
   <dc:creator>Parellada Redondo, María José</dc:creator>
   <dc:subject>615.01</dc:subject>
   <dc:subject>615.03</dc:subject>
   <dc:subject>615.21</dc:subject>
   <dc:subject>615.214</dc:subject>
   <dc:subject>Antipsychotics</dc:subject>
   <dc:subject>LPS</dc:subject>
   <dc:subject>Neuroinflammation</dc:subject>
   <dc:subject>Risperidone</dc:subject>
   <dc:subject>Schizophrenia</dc:subject>
   <dc:subject>Ciencias Biomédicas</dc:subject>
   <dc:subject>32 Ciencias Médicas</dc:subject>
   <dc:description>Inflammation, caused by both external and endogenous factors, has been implicated as a main pathophysiological feature of chronic mental illnesses, including schizophrenia. An increase in pro-inflammatory cytokines has been described both in experimental models and in schizophrenia patients. However, not much is known about the effects that antipsychotic drugs have on intra- and intercellular mechanisms controlling inflammation. The aim of the present study was to investigate the possible anti-inflammatory effect of a standard schizophrenia treatment not only at the level of soluble mediators, but also at intra- and intercellular inflammatory pathways. The present study was conducted in a model of mild neuroinflammation using a lipopolysaccharide (LPS) challenge that was not an endotoxaemic dose (0.5 mg/kg i.p.) in young adult rats. Main results: single doses of risperidone (0.3–3.0 mg/kg i.p.) prevented increased inflammatory parameters induced by LPS in brain cortex [expression of inflammatory cytokines, interleukin (IL)-1β and tumour necrosis factor (TNF)-α, activity of the inducible inflammatory enzymes nitric oxide synthase and cyclooxygenase, p38 mitogen-activated protein kinase (MAPK) and inflammatory nuclear transcription factor κB] and restored anti-inflammatory pathways decreased by LPS challenge (deoxyprostaglandins and peroxisome proliferator activated receptor γ). This is the first study demonstrating that risperidone elicits a preventive effect on the anti-inflammatory arm of the homeostatic mechanism controlling inflammation in a model of mild encephalitis in rats. Our findings suggest a possible protective effect of risperidone on brain cells.</dc:description>
   <dc:description>Instituto de Salud Carlos III</dc:description>
   <dc:description>Ministerio de Ciencia e Innovación (España) </dc:description>
   <dc:description>Centro de Investigación Biomédica En Red de Salud Mental</dc:description>
   <dc:description>Depto. de Farmacología y Toxicología</dc:description>
   <dc:description>Depto. de Medicina Legal, Psiquiatría y Patología</dc:description>
   <dc:description>Fac. de Medicina</dc:description>
   <dc:description>TRUE</dc:description>
   <dc:description>pub</dc:description>
   <dc:date>2024-01-29T10:45:39Z</dc:date>
   <dc:date>2024-01-29T10:45:39Z</dc:date>
   <dc:date>2013</dc:date>
   <dc:type>journal article</dc:type>
   <dc:type>VoR</dc:type>
   <dc:identifier>https://hdl.handle.net/20.500.14352/95862</dc:identifier>
   <dc:identifier>1469-5111</dc:identifier>
   <dc:identifier>10.1017/s1461145711001775</dc:identifier>
   <dc:identifier>1461-1457</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>FIS 10/123</dc:relation>
   <dc:relation>MacDowell KS, García-Bueno B, Madrigal JL, Parellada M, Arango C, Micó JA, Leza JC. Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. Int J Neuropsychopharmacol. 2013 Feb;16(1):121-35. doi: 10.1017/S1461145711001775.  PMID: 22176740.</dc:relation>
   <dc:rights>restricted access</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>Oxford University Press</dc:publisher>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>